Skip navigation
Value-Based Healthcare
Report

Value-Based Healthcare

The Implications for Pharma Strategy

EIU, 2014

auto-generated audio
auto-generated audio

Editorial Rating

7

Qualities

  • Innovative
  • Eye Opening
  • Overview

Recommendation

The system of how medical care providers get reimbursed has undergone – and is continuing to undergo – tremendous change. Under the umbrella of “value-based health care” (VBH), the quality of patients’ case results determines the payments to medical providers and health care suppliers – rather than the quantity of tests, procedures or medications a patient receives. Experts at the Economist Intelligence Unit succinctly describe how these changes will affect the big pharmaceutical companies that create and market medications to millions of people. Their report offers compelling examples of how these firms can cope with and benefit from VBH. getAbstract recommends this illuminating report on the shake-up in health care to pharma professionals, health care providers and suppliers, as well as entrepreneurs and investors in the medical arena.

Take-Aways

  • With “value-based health care” (VBH), reimbursers pay medical providers based on the quality of care, not the quantity of care (the number of tests, procedures or drugs).
  • “Patient outcomes” – how successful treatments are – indicates the quality of care.
  • The trend toward VBH poses specific challenges for the pharmaceutical industry.

About the Author

The Economist Intelligence Unit Healthcare provides information to aid health care providers, suppliers, payers and others in developing research- and evidence-based business plans.


More on this topic

By the same author

8
Article
7
Report
7
Report
8
Report
7
Report
8
Report
8
Report
7
Report
8
Report
7
Report
8
Report
7
Report
7
Report
7
Report
8
Report
8
Report